CD274 and breast carcinoma: Although PD-L1 is mainly a membrane protein, Ghebeh et al.14 reported that treatment with doxorubicin downregulates cell surface PD-L1 expression and upregulates its nuclear expression in breast cancer cells, making them chemoresistant.